Grant of Share Options to Directors and Employees (1446Y)
17 December 2010 - 6:00PM
UK Regulatory
TIDMMDST
RNS Number : 1446Y
Medicsight Plc
17 December 2010
Press Release 17 December 2010
Medicsight PLC
("Medicsight" or "the Company")
Grant of Share Options to Directors and Employees
Medicsight (AIM:MDST), industry leader in the development of
Computer-Aided Detection (CAD) and image analysis software which
assists in the early detection and diagnosis of disease, today
announces approval of a new share option scheme ("scheme M") and
the grant of options to subscribe for ordinary shares of 5 pence
each in the Company. Under scheme M, one sixth of the options
granted become exercisable at a price of 5 pence per share at six
monthly intervals post grant date between 16 December 2010 and 16
December 2013.
Tim Paterson-Brown, Allan Rowley and Troy Robinson, Executive
Directors, have on 13 December been granted 2,125,000, 1,000,000
and 1,200,000 scheme M options respectively. Following the grant of
these share options, the Executive Directors' interests share
options are set out below:
Number of share
Existing share options granted Total share
options held: under scheme M: options:
------------------- ------------------ ----------------- ------------------
Tim Paterson-Brown 875,000 2,125,000 3,000,000
Allan Rowley 2,000,000 1,000,000 3,000,000
Troy Robinson 300,000 1,200,000 1,500,000
A total of 5,380,000 options have been granted.
- ENDS -
For further information:
Medicsight plc
Allan Rowley, CEO Tel: +44 (0)20 7605
7950
www.medicsight.com
Daniel Stewart & Co
Emma Earl / Oliver Rigby Tel: +44 (0) 207 776
6550
www.danielstewart.co.uk
Media enquiries:
Abchurch
www.abchurch-group.com
Heather Salmond Tel: +44 (0) 207 398
7704
heather.salmond@abchurch-group.com
Simone Elviss Tel: +44 (0) 207 398
7728
simone.elviss@abchurch-group.com
Quincy Allan Tel: +44 (0) 207 398
7710
quincy.allan@abchurch-group.com
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading
developer of computer-aided detection (CAD) and image analysis
software for the medical imaging market. The CAD software
automatically highlights suspicious areas on computerised
tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early
indicators of disease. Medicsight's CAD software has been validated
using one of the world's largest and most population diverse
databases of verified patient CT scan data. Medicsight's
ColonCAD(TM) and LungCAD(TM) software products are seamlessly
integrated with the advanced 3D visualisation workstations of
several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware
such as Multi-Detector CT scanners, radiologists are facing a
growing challenge in the amount of detailed patient image data that
they must review for each patient examination. Some CT scan
examinations generate as many as 2000 images per patient. Review of
this data by the radiologist is not only time-consuming but also
prone to error due to reader fatigue. CAD software can help the
reviewing radiologist by analysing the image data and automatically
highlighting suspicious regions of interest for closer inspection.
Without CAD software some potential abnormalities or areas of
disease may be overlooked. This can be critical for diagnosis and
the management of patient outcomes as early detection of disease
greatly increases the probability of successful treatment and a
positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT
interpretation across both individuals and institutions thereby
supporting population based screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an
advanced CAD algorithm to analyse CT scans of the colon and lung
and automatically highlight suspicious areas that may be indicators
of disease. CAD may highlight areas easily overlooked by the
reviewing radiologist, such as small lesions or regions that are
hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D
visualisation platforms of industry-leading imaging equipment
partners. The integrated systems provide sophisticated image
viewing capabilities, including 3D reconstructed image data, with
the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease.
This allows clinical end users to perform either a 'second read',
where CAD findings are displayed to the user after completion of an
initial review of the CT scan data, or a 'concurrent read' where
CAD findings are displayed during the user's initial review of the
original CT scan images.
Since inception, Medicsight has developed close and lasting
relationships with some of the world's foremost clinicians in
product related areas. This provides the Company with a wealth of
clinical expertise and dedicated clinical research to support
ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research
programmes worldwide to develop the Company's comprehensive
database of population diverse verified patient CT scan data, thus
allowing Medicsight's products to be validated to the highest
possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSFFWFWMFSSELE
Medicsight (LSE:MDST)
Historical Stock Chart
From Dec 2024 to Jan 2025
Medicsight (LSE:MDST)
Historical Stock Chart
From Jan 2024 to Jan 2025
